- Home
- STNG vs CELC Comparison
STNG vs CELC Comparison
Compare STNG & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STNG | CELC |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | STNG | CELC |
|---|---|---|
| Price | $72.39 | $107.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $79.00 | ★ $100.13 |
| AVG Volume (30 Days) | ★ 975.6K | 647.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.62 | $7.58 |
| 52 Week High | $73.30 | $120.32 |
Technical Indicators
Market Signals| Indicator | STNG | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 71.88 | 50.23 |
| Support Level | $57.95 | $97.75 |
| Resistance Level | N/A | $114.54 |
| Average True Range (ATR) | 2.32 | 5.26 |
| MACD | 0.16 | -0.39 |
| Stochastic Oscillator | 91.09 | 66.64 |
Price Performance
Historical ComparisonAbout STNG Scorpio Tankers Inc.
Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owned, lease financed, or chartered in vessels spanning three different vessel segments Handymax, MR, and LR2. The company's fleet of tankers is the eco-friendly, and newest fleet on the water hauling clean petroleum products. It provides seaborne transportation of crude oil and refined petroleum products. The company generates the majority of its revenue from LR2.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.